mCRPC – treatment options, different patient needs: where does targeted alpha treatment fit in?

Virtuellt on demand symposium
• Access anytime at your convenience from Friday, 6th May at 12.00 to Tuesday, 10th May
• Join our live session with Q&A on Tuesday, 10th May 2022 at 17.00

Introduction. Dr. Daniel Heinrich. 4 minutes

Metastatic castration resistent prostate cancer/mCRPC): A personalised treatment approach. Prof. Bertrand Tombal.30 minutes

The evolving role of PSA response: Aligning expectations with prostate cancerstage and treatment. Prof. Jürgen E. Gschwend. 15 minutes

Making the right treatment sequencing decisions in mCRPC. Prof. Joe O’Sullivan. 30 minutes

Considerations for mCRPC management during the COVID-19 pandemic. Prof. Joe O’Sullivan. 10 minutes

Skandinaviska moderatorer är Dr. Daniel Heinrich (ordförande; Norge), Dr. Sten Nilsson (Sverige) och Dr. Gedske Daugaard (Danmark). De kommer att diskutera symposiet och svara på era frågor under den sammanfattande livesända sessionen, tisdagen den 10 maj kl 17.00–18.00.

För mer information och anmälan klicka här